These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 11394499)

  • 21. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
    Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
    Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue.
    Shi Y; Huang W; Tan Y; Jin X; Dua R; Penuel E; Mukherjee A; Sperinde J; Pannu H; Chenna A; DeFazio-Eli L; Pidaparthi S; Badal Y; Wallweber G; Chen L; Williams S; Tahir H; Larson J; Goodman L; Whitcomb J; Petropoulos C; Winslow J
    Diagn Mol Pathol; 2009 Mar; 18(1):11-21. PubMed ID: 19214113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope.
    Sotiriadou R; Perez SA; Gritzapis AD; Sotiropoulou PA; Echner H; Heinzel S; Mamalaki A; Pawelec G; Voelter W; Baxevanis CN; Papamichail M
    Br J Cancer; 2001 Nov; 85(10):1527-34. PubMed ID: 11720440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stimulation of cells from a non-invaded and an invaded lymph node with a HER-2+ tumor with peptides corresponding to T-cell epitopes E75 and G89 induced expansion of central memory cells (TCM) from the metastasis-negative lymph nodes.
    Ko BK; Efferson CL; Kawano K; Kuerer HM; Sahin A; Murray JL; Ioannides CG
    Int J Oncol; 2004 Jun; 24(6):1413-8. PubMed ID: 15138582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
    Gong Y; Booser DJ; Sneige N
    Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HER2 testing: a review of detection methodologies and their clinical performance.
    Laudadio J; Quigley DI; Tubbs R; Wolff DJ
    Expert Rev Mol Diagn; 2007 Jan; 7(1):53-64. PubMed ID: 17187484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
    Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K
    Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas.
    Nunes CB; Rocha RM; Reis-Filho JS; Lambros MB; Rocha GF; Sanches FS; Oliveira FN; Gobbi H
    J Clin Pathol; 2008 Aug; 61(8):934-8. PubMed ID: 18474540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer.
    Mittendorf EA; Gurney JM; Storrer CE; Shriver CD; Ponniah S; Peoples GE
    Surgery; 2006 Mar; 139(3):407-18. PubMed ID: 16546506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer.
    Woll MM; Hueman MT; Ryan GB; Ioannides CG; Henderson CG; Sesterhan IA; Shrivasta S; McLeod DG; Moul JW; Peoples GE
    Int J Oncol; 2004 Dec; 25(6):1769-80. PubMed ID: 15547716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.
    Rentzsch C; Kayser S; Stumm S; Watermann I; Walter S; Stevanoviç S; Wallwiener D; Gückel B
    Clin Cancer Res; 2003 Oct; 9(12):4376-86. PubMed ID: 14555509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study.
    Short SM; Yoder BJ; Tarr SM; Prescott NL; Laniauskas S; Coleman KA; Downs-Kelly E; Pettay JD; Choueiri TK; Crowe JP; Tubbs RR; Budd TG; Hicks DG
    Breast J; 2007; 13(2):130-9. PubMed ID: 17319853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preferential detection of catalytically inactive c-erbB-2 by antibodies to unphosphorylated peptides mimicking receptor tyrosine autophosphorylation sites.
    Epstein RJ
    Oncogene; 1995 Jul; 11(2):315-23. PubMed ID: 7624146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients.
    Pupa SM; Ménard S; Andreola S; Colnaghi MI
    Cancer Res; 1993 Dec; 53(24):5864-6. PubMed ID: 7903196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multisite phosphotyping of the ErbB-2 oncoprotein in human breast cancer.
    Ouyang X; Gulliford T; Huang GC; Harper-Wynne C; Shousha S; Epstein RJ
    Mol Diagn; 2001 Mar; 6(1):17-25. PubMed ID: 11257208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p95HER2 and breast cancer.
    Arribas J; Baselga J; Pedersen K; Parra-Palau JL
    Cancer Res; 2011 Mar; 71(5):1515-9. PubMed ID: 21343397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Establishment of a B16 cell line stably expressing genes encoding HER2 multi-epitope peptides in vivo].
    Li H; Xiang ZM; Wu XL; Wang L; Wei HF; Wan M; Wang LY; Yu YL
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Jan; 25(1):13-5. PubMed ID: 19126380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a cell-surface antigen (LEA.135) associated with favorable prognosis in human breast cancer.
    Imam SA; Esteban EF; Chen RS; Cardiff RD; Taylor CR
    Cancer Res; 1993 Jul; 53(14):3233-6. PubMed ID: 7686814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.
    Peoples GE; Goedegebuure PS; Smith R; Linehan DC; Yoshino I; Eberlein TJ
    Proc Natl Acad Sci U S A; 1995 Jan; 92(2):432-6. PubMed ID: 7831305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cryptic epitopes induce high-titer humoral immune response in patients with cancer.
    Fischer E; Kobold S; Kleber S; Kubuschok B; Braziulis E; Knuth A; Renner C; Wadle A
    J Immunol; 2010 Sep; 185(5):3095-102. PubMed ID: 20660712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.